Poolbeg Pharma PLC is a clinical-stage biotechnology company focused on developing innovative medicines in oncology, immunology, infectious diseases, and metabolic disorders. The company's strategy emphasizes identifying high-value assets, advancing them efficiently through clinical development, and creating value through licensing and commercial partnerships.
Genus, the FTSE 250 animal-genetics company, rose 3.8% to 2,288p on 5 August 2026 as investors continued to reappraise its recovery prospects. In a July trading update the group said full-year 2026 profit would come in moderately ahead of market expectations, at around £98m …
AstraZeneca, Britain's most valuable listed company, rebounded 3.7% to 12,176p on 5 August 2026 after reports of a possible mega-merger with Bristol Myers Squibb were played down. The shares had fallen sharply earlier in the week on reports of preliminary talks over a roughly …
Poolbeg Pharma is a clinical-stage biopharmaceutical company focused primarily on developing medicines that address complications associated with cancer immunotherapy. Its lead programme, POLB 001, is being evaluated as a potential preventive treatment for cytokine release syndrome, a serious inflammatory reaction associated with certain cancer …
EDX Medical Group PLC is a healthcare diagnostics company focused on developing and commercialising advanced diagnostic products and digital healthcare solutions for cancer, cardiovascular disease, infectious diseases and other serious medical conditions. The company combines laboratory diagnostics, digital technologies and clinical expertise to support …
MicroSalt plc is a food technology company focused on developing proprietary low-sodium salt solutions designed to reduce sodium content without compromising taste. The company's innovative technology addresses one of the food industry's most significant health challenges by enabling food manufacturers to produce healthier products …
ValiRx PLC attracted significant investor attention after its shares climbed approximately10.50%during trading on5 August 2026. The strong rally reflected improving confidence across the biotechnology sector as investors increasingly focused on companies developing innovative therapies targeting high-value medical conditions.
LSE:BIOG – Biotech Growth Trust PLCfinished among the stronger-performing London-listed investment trusts after gaining approximately2.22%on 5 August 2026, reflecting renewed investor optimism towards the global biotechnology sector.
Futura Medical plc attracted significant investor attention after its shares climbed approximately11.42%during trading on5 August 2026. The strong rally reflected improving confidence in healthcare companies transitioning from product development towards broader commercial expansion and revenue growth.
•LSE:GENIdeclined8.11%during trading on5 August 2026, making it one of the biggest healthcare sector fallers on the London market.